Clinical trials: Stage 5 Chronic Kidney Diseases
Chronic Kidney Disease, Hyperphosphatemia
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a…
- Trial name
- NCT00416520
- Testing
- MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®), Another phosphate binder (Sevelamer)
- Where
- 68 sites in Australia, Austria and 9 more
- Volunteers
- 336 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease, Dialysis
Dose-finding Study of MCI-196
The Primary Objective of this study is to determine the initial starting doses of colestilan (MCI-196) in paediatric subjects with Chronic Kidney Disease Stage 5 on Dialysis and with Hyperphosphataemia.
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Paediatric
- Trial name
- NCT01814904
- Testing
- colestilan-L, colestilan-M, colestilan-H
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease 5D
Intradialytic Exercise Combined With Creatine Monohydrate in Patients With Chronic Kidney Disease Undergoing Hemodialysis.
This study aims to evaluate the effects of creatine monohydrate supplementation and an intradialytic exercise program on body composition, biochemical parameters, and functional capacity in patients with chronic kidney disease…
- Trial name
- NCT07666815
- Testing
- Group A with creatine monohydrate, Group C Intradialytic Exercise Program, Comparison group D Hemodialysis
- Where
- Mexico
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pedro Julian Flores Moreno
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis
To evaluate the efficacy of fasiglifam 50 mg once daily compared to placebo on glycemic control as measured by glycosilated haemoglobin (HbA1c) over a 16-week treatment period in participants with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT02015780
- Testing
- Fasiglifam, Antihyperglycemic therapy
- Where
- 30 sites in United States, Bulgaria and 5 more
- Sponsor
- Takeda
Chronic Kidney Disease Stage 5, Mineral Metabolism Disorder
Acute Changes in the Mineral Metabolism After a High Phosphorous Containing Meal in Dialysis Patients
The purpose of the study is to investigate whether a high phosphorous containing meal causes acute changes in p-phosphate levels in patients with dialysis-dependent kidney failure.
- Trial name
- NCT03868371
- Testing
- High phosphorous containing meal, Low phosphorous containing meal
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Herlev Hospital
Chronic Kidney Disease (CKD) Stage 5, Kidney Dysfunction Requiring Dialysis (KDRD)
Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)
In this pragmatic clinical trial, which will dovetail with Veterans' routine outpatient dialysis clinic visits in six VA medical centers, the investigators will study 252 Veterans with kidney disease who need to start dialysis…
- Conditions
- Chronic Kidney Disease (CKD) Stage 5, Kidney Dysfunction Requiring Dialysis (KDRD), Dialysis Dependency
- Trial name
- INCHVETS (NCT05465044)
- Testing
- Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule, Thrice-Weekly Hemodialysis
- Where
- 8 sites in United States
- Volunteers
- 252 people
- Sponsor
- VA Office of Research and Development
Chronic Kidney Diseases, Chronic Kidney Disease stage3
Validation and Evaluation of a Newly Developed Mobile Diet App
A 12-week, prospective, multicenter, open-label pilot randomized controlled trial (RCT) will be carried out to determine the feasibility, acceptability and potential clinical efficacy of a newly developed mobile diet app among…
- Conditions
- Chronic Kidney Diseases, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5
- Trial name
- NCT04336033
- Testing
- Counseling, Renal Diet App, Printed Nutrition Pamphlet
- Where
- Malaysia
- Volunteers
- 90 people
- Sponsor
- Universiti Putra Malaysia
Chronic Kidney Disease Stage 5, Dialysis
An Evaluation of the KCCQ Score in Predicting Cardiovascular Risk in Dialysis Patients
Cardiovascular Disease (CVD) is the main complication and the most important cause of death in CKD patients. As the disease progresses, the incidence of cardiovascular disease in CKD patients gradually increases, especially in…
- Conditions
- Chronic Kidney Disease Stage 5, Dialysis, Heart Failure
- Trial name
- NCT06542016
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Shenzhen Second People's Hospital
Chronic Kidney Disease, Dialysis
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal…
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00506441
- Testing
- MCI-196
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 245 people
- Sponsor
- Tanabe Pharma Corporation
CKD Stage 5
Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V
The Investigators plan to conduct a long-term trial to explore therapeutic implications of effervescent calcium magnesium citrate (EffCaMgCit) in CKD Stage V (end stage renal disease on hemodialysis).
- Trial name
- NCT03565913
- Testing
- EffCaMgCit, CaAcS
- Where
- United States
- Volunteers
- 269 people
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Kidney Disease, Hyperphosphatemia
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia…
- Conditions
- Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia, Renal Insufficiency
- Trial name
- 05D (NCT02492620)
- Testing
- Ferric Citrate
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Denver Nephrologists, P.C.
Anemia
An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis
This observational study will evaluate the efficacy and use of Methoxy polyethylene glycol-epoetin beta (Mircera) in participants with Stage V chronic kidney disease on hemodialysis receiving an erythropoietin prior to study…
- Trial name
- NCT01940484
- Testing
- Methoxy polyethylene glycol epoetin beta
- Where
- 10 sites in South Africa
- Volunteers
- 98 people
- Sponsor
- Hoffmann-La Roche
Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis)
Blood Pressure Lowering in Dialysis (BOLD) Trial
Blood pressure may be one of the most important modifiable risk factors for cardiovascular disease in patients with end-stage-renal-disease undergoing maintenance hemodialysis.
- Conditions
- Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis), Chronic Kidney Diseases, Chronic Kidney Disease Stage 5
- Trial name
- BOLD (NCT03459807)
- Testing
- Anti-Hypertensive medications, Dry Weight Adjustment
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Chronic Kidney Disease, Secondary Hyperparathyroidism
Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
This study will compare CTAP201 with Doxercalciferol in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), undergoing regular hemodialysis, at different dose strengths.
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
- Trial name
- NCT00792857
- Testing
- CTAP201 Injection, Doxercalciferol
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- OPKO IP Holdings II, Inc.
COVID-19, Chronic Kidney Disease stage4
Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir
Nirmatrelvir-ritonavir is approved for coronavirus disease 2019 (COVID-19) but not initially recommended in patients with severe renal impairment.
- Conditions
- COVID-19, Chronic Kidney Disease stage4, Chronc Kidney Disease Stage 5
- Trial name
- NCT05624840
- Testing
- Nirmatrelvir/ritonavir
- Where
- Hong Kong
- Volunteers
- 85 people
- Sponsor
- Chinese University of Hong Kong
Anemia of Chronic Kidney Disease
A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia
The objective of the study is to evaluate the efficacy and safety of KRX-0502, administered without food, in treating iron deficiency anemia in subjects with stage 3 to 5 non-dialysis dependent chronic kidney disease (NDD-CKD).
- Trial name
- NCT02128074
- Testing
- KRX-0502
- Where
- 3 sites in Israel
- Volunteers
- 32 people
- Sponsor
- Keryx Biopharmaceuticals
End Stage Renal Disease
Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis
Although exercise training of haemodialysis patients is associated with generally positive outcomes few haemodialysis units routinely offer intradialytic exercise therapy.
- Trial name
- NCT02832440
- Testing
- Exercise programmes
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Cardenal Herrera University
End-Stage Renal Disease, Stage 5 Chronic Kidney Disease
Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
Chronic Kidney Disease Stage 5 (CKD5) patients receiving maintenance hemodialysis are at an increased risk for developing bloodstream infections.
- Trial name
- NCT02392208
- Testing
- Telavancin, Pharmacokinetic Blood Sampling
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Michigan
Chronic Kidney Disease Stage V, End-Stage Renal Disease
Autogenic Relaxation and Murottal Therapy in Hemodialysis Patients
This quasi-experimental study aims to evaluate the effect of combined autogenic relaxation and Surah Ar-Rahman murottal therapy on anxiety, sleep quality, and hemodynamic parameters in hemodialysis patients.
- Conditions
- Chronic Kidney Disease Stage V, End-Stage Renal Disease, Hemodialysis
- Trial name
- AR-MHD (NCT07412548)
- Testing
- Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy, listening to dangdut music
- Where
- Indonesia
- Volunteers
- 76 people
- Sponsor
- Universitas Muhammadiyah Surakarta
Resting Energy Expenditure, Chronic Kidney Disease
Novel Equation for Estimating Resting Energy Expenditure
The energy and nutrition states are closely associated with CKD patients complications and outcomes.To reach the energy balance target, we need the accurate resting energy expenditure level of patients.
- Trial name
- NCT03377413
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital